Results demonstrated that KLTi combined with chemotherapy significantly improved the levels of CD3+ (MD = 8.58, 95% CI 6.13–11.04), CD4+ (MD = 6.38, 95% CI 4.93–7.83), CD8+ (MD = 1.50, 95% CI −0.31–3.32), CD4+/CD8+ (MD = 0.32, 95% CI 0.25–0.39), and NK cells count (MD = 10.58, 95% CI 7.27–13.90) in NSCLC patients. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.